A Case of Akathisia After Switching From Branded to Generic High-Dose Olanzapine

Joseph F. Goldberg, MD

Published: April 15, 2012

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

As many established atypical antipsychotics lose patent exclusivity, use of generic atypical antipsychotics will expectably rise in light of cost. US Food and Drug Administration (FDA) approval of generic drugs requires demonstration of bioequivalence of a generic agent (specifically, a plasma C and area under the curve [AUC] falling within a 90% confidence interval of 80%-125% of that achieved with a branded formulation) but no required evaluation of efficacy or tolerability. Limited data make it difficult for clinicians to advise patients on when less-expensive generic formulations differ from branded drugs in efficacy or adverse effects.

J Clin Psychiatry 2012; 73(4): 497

© 2012 Physicians Postgraduate Press, Inc.’ ‹

Volume: 73

Quick Links: Movement Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder

Prevalence and correlates of obsessive-compulsive symptoms and OCD were identified from the case records of over 22,500...

Read More...